David Golod, PhD, MBA
David Golod, PhD, MBA
Clinical Operations & Program Strategy
David Golod, PharmD, MBA, brings 25+ years of biopharmaceutical industry experience spanning all phases of development and more than 10 therapeutic areas. With a unique blend of biomedical engineering and pharmaceutical business acumen, he seamlessly integrates patient needs, scientific progress, and business goals to shape developmental strategies. Prior to joining Celea, David served as Senior Director, Clinical Development Execution at Vertex Pharmaceuticals as well as Vice President of Clinical Operations at Flexion Therapeutics and Goldfinch Bio.
“What stands out about Celea, is our patient-first culture and commitment to developing therapies that meet the real-world experiences and needs of people living with IPF.
Our completed Phase 2b trial and initiated Phase 3 SURPASS-IPF trial have been designed to rigorously evaluate the therapeutic strength of deupirfenidone to ensure we are delivering a truly transformative treatment option.”